Juno Therapeutics (JUNO) Misses Q2 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Juno Therapeutics Reports Second Quarter 2015 Financial Results
August 12, 2015 4:05 PM EDT-- JCAR015 IND FDA clearance allows initiation of Juno's first pivotal trial -- -- Transformative partnership with Celgene -- -- Substantial R&D progress with key acquisition integrations on track -- -- Conference call to be held today at 5:00pm Eastern Time
SEATTLE, Aug. 12, 2015 (GLOBE NEWSWIRE) -- Juno Therapeutics, Inc. (NASDAQ: JUNO), a biopharmaceutical company focused on re-engaging the body's immune system to revolutionize the treatment of cancer, today reported business highlights and financial results for the second... More
Juno Therapeutics Reports Second Quarter 2015 Financial Results
August 12, 2015 4:05 PM EDT-- JCAR015 IND FDA clearance allows initiation of Juno's first pivotal trial -- -- Transformative partnership with Celgene -- -- Substantial R&D progress with key acquisition integrations on track -- -- Conference call to be held today at 5:00pm Eastern Time
SEATTLE, Aug. 12, 2015 (GLOBE NEWSWIRE) -- Juno Therapeutics, Inc. (NASDAQ: JUNO), a biopharmaceutical company focused on re-engaging the body's immune system to revolutionize the treatment of cancer, today reported business highlights and financial results for the second... More
